(800) 429-3205

Submit Your Information for the Viatris Lawsuit

Lead plaintiff deadline is June 3, 2025.

If you purchased or acquired Viatris securities between August 8, 2024 through February 26, 2025, please contact Berger Montague using the form below.

Please view our terms of use policy and our privacy policy.

First Name *

Last Name *

Email *

Phone Number *

Address

City

Zip

State

Are you a current or former employee of Viatris?

How many shares did you purchase? Please provide ALL transactions.

What dates did you purchase? Please provide ALL dates.

What was the price per share when you purchased? Please provide ALL prices.

Terms of Use *

I agree to the terms of service

Subscribe

I would like to receive updates from Berger Montague

Thank you! Your form has been successfully submitted.

About the Lawsuit

According to the lawsuit, defendants misled investors by, among other things, minimizing the impact of the failed inspection at Viatris’ Indore, India facility and Warning Letter from the U.S. Food and Drug Administration.

The suit alleges that on February 27, 2025, investors learned the truth when Viatris announced its financial results for Q4 and full-year 2024, providing disappointing 2025 guidance due to “the expected financial impact from Indore facility warning letter and import alert.”

On this news, the price of Viatris common stock fell more than 15%, or $1.71 per share, from a closing price of $11.24 per share on February 26, 2025 to a close of $9.53 per share on February 27.

Investors who purchased or acquired Viatris securities between August 8, 2024 through February 26, 2025, may no later than June 3, 2025, seek to be appointed as a lead plaintiff representative of the class.